Company news
Orion Corp. (KRX:271560) news
Orion Corp. news releases on 6ix. Latest, Sep 30, 2026: Orion Corporation completed share acquisitions
Press releases & updates
Orion Corporation completed share acquisitions
September 30, 2026
Orion Corporation: Acquisition of own shares during week 40, 2026
September 30, 2026
Orion Corporation: Acquisition of own shares during week 39, 2026
September 25, 2026
Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
July 3, 2026
105,950 Orion Corporation A shares converted into B shares
May 15, 2026
Composition of the Nomination Committee of Orion Corporation
April 27, 2026
Orion Group Interim report January–March 2026
April 23, 2026
Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
April 23, 2026
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
April 20, 2026
Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026
April 10, 2026
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
April 1, 2026
Decisions taken by Orion Corporation's Annual General Meeting and Board of Directors' organising meeting on 24 March 2026
March 24, 2026
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
March 18, 2026
Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
March 10, 2026
Orion Group Financial Statement documents 2025 and Remuneration Report published
February 27, 2026
The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons
February 12, 2026
Notice to the Annual General Meeting of Orion Corporation
February 12, 2026
Orion Group Financial Statement Release January–December 2025
February 12, 2026
62,752 Orion Corporation A shares converted into B shares
February 3, 2026
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
January 30, 2026
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
January 20, 2026
182,827 Orion Corporation A shares converted into B shares
January 16, 2026
Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting
January 15, 2026
Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
January 14, 2026
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
January 14, 2026
Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
January 8, 2026
Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025
December 3, 2025
71,498 Orion Corporation A shares converted into B shares
November 27, 2025
Orion receives award for international growth from the President of the Republic of Finland
November 14, 2025
Orion Group Interim Report January–September 2025
October 28, 2025
49,164 Orion Corporation A shares converted into B shares
October 24, 2025
Orion and Abzena announce exclusive commercial license for Abzena’s antibody
October 23, 2025
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
October 14, 2025
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
September 30, 2025
80,802 Orion Corporation A shares converted into B shares
September 19, 2025
337,000 Orion Corporation A shares converted into B shares
August 20, 2025
Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries
August 13, 2025
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
August 8, 2025
Orion Corporation: Managers’ transactions – Satu Ahomäki
August 4, 2025
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
July 29, 2025
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
July 21, 2025
Orion Group Half-Year Financial Report January–June 2025
July 18, 2025
Orion Corporation’s financial reporting and Annual General Meeting in 2026
July 18, 2025
Inside information: Orion upgrades full-year outlook for 2025
July 9, 2025
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
July 4, 2025
141,959 Orion Corporation A shares converted into B shares
June 23, 2025